Dr. Bharadwaj grew up in India and came to the United States for her graduate studies. She completed her Ph.D. in Biomedical Engineering at Arizona State University. Her doctoral work focused on preclinical studies investigating nanoparticle delivery across the blood-brain barrier after traumatic brain injury. In 2018, she joined Drs. Porreca and Anderson laboratories at the University of Arizona for postdoctoral training. Her postdoctoral work focused on identifying the critical role of dorsal pons neurons in the migraine pain pathway. Currently, she continues her migraine research in Dr. Yeomans’s lab at Stanford Medicine. Dr. Bharadwaj is also currently involved in post-traumatic headache research in Dr. David Clark's laboratory at the Veterans Affairs (Palo Alto). Recently, she was awarded the prestigious International Headache Society Fellowship for investigating mechanisms for migraine pain generation. Over the years, she has held several leadership positions including serving as the communications director for Stanford Postdoctoral Association, as a diversity, equity, and inclusion Ally for the American Headache Society, and as an assistant editorial team member for the Headache journal.
Honors & Awards
International Headache Society Fellowship, International Headache Society (July 2021-July 2022)
Sursum fellow, Postdoctoral research development grant, University of Arizona (June 2019-June 2020)
STAR (Student Travel Achievement Recognition) award, Society for Biomaterials (2019, 2017)
Graduate college completion fellowship, Arizona State University (Spring 2018)
Outstanding mentor award, Graduate and Professional Student Association, Arizona State University (April 2018)
Outstanding achievement award - Honorary mention, Society for Biomaterials (2018)
Boards, Advisory Committees, Professional Organizations
Communications Director, Stanford Postdoctoral Association (SURPAS) (2021 - Present)
Secretary/Treasurer of Nanomaterials SIG, Society for Biomaterials (2019 - Present)
Assistant Editorial Team, Headache (2021 - Present)
Review Editor, Frontiers in Pain Research (Headache) (2021 - Present)
Reviewer board member, Pharmaceutics (2021 - Present)
Diversity, Equity, and Inclusion Ally, American Headache Society (2021 - Present)
Social media manager, Stanford Postdoctoral Association (SURPAS) (2021 - 2021)
Social media and communication chair, Graduate Women in Science, Arizona chapter (2018 - 2021)
Doctor of Philosophy, Arizona State University (2018)
Bachelor of Engineering, Unlisted School (2011)
Master of Science, Arizona State University (2013)
A new hypothesis linking oxytocin to menstrual migraine.
OBJECTIVE: To highlight the emerging understanding of oxytocin (OT) and oxytocin receptors (OTRs) in modulating menstrual-related migraine (MRM).BACKGROUND: MRM is highly debilitating and less responsive to therapy, and attacks are of longer duration than nonmenstrually related migraine. A clear understanding of the mechanisms underlying MRM is lacking.METHODS: We present a narrative literature review on the developing understanding of the role of OT and the OTR in MRM. Literature on MRM on PubMed/MEDLINE database including clinical trials and basic science publications was reviewed using specific keywords.RESULTS: OT is a cyclically released hypothalamic hormone/neurotransmitter that binds to the OTR resulting in inhibition of trigeminal neuronal excitability that can promote migraine pain including that of MRM. Estrogen regulates OT release as well as expression of the OTR. Coincident with menstruation, levels of both estrogen and OT decrease. Additionally, other serum biochemical factors, including magnesium and cholesterol, which positively modulate the affinity of OT for OTRs, both decrease during menstruation. Thus, during menstruation, multiple menstrually associated factors may lead to decreased circulating OT levels, decreased OT affinity for OTR, and decreased expression of the trigeminal OTR. Consistent with the view of migraine as a threshold disorder, these events may collectively result in decreased inhibition promoting lower thresholds for activation of meningeal trigeminal nociceptors and increasing the likelihood of an MRM attack.CONCLUSION: Trigeminal OTR may thus be a novel target for the development of MRM therapeutics.
View details for DOI 10.1111/head.14152
View details for PubMedID 34125955
Platelet-like particles reduce coagulopathy-related and neuroinflammatory pathologies post-experimental traumatic brain injury
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS
Coagulopathy may occur following traumatic brain injury (TBI), thereby negatively affecting patient outcomes. Here, we investigate the use of platelet-like particles (PLPs), poly(N-isopropylacrylamide-co-acrylic-acid) microgels conjugated with a fibrin-specific antibody, to improve hemostasis post-TBI. The objective of this study was to diminish coagulopathy in a mouse TBI model (controlled cortical impact) via PLP treatment, and subsequently decrease blood-brain barrier (BBB) permeability and neuroinflammation. Following an acute intravenous injection of PLPs post-TBI, we analyzed BBB permeability, ex vivo coagulation parameters, and neuroinflammation at 24 hr and 7 days post-TBI. Both PLP-treatment and control particle-treatment had significantly decreased BBB permeability and improved clot structure 24 hr post-injury. Additionally, no significant change in tissue sparing was observed between 24 hr and 7 days for PLP-treated cohorts compared to that observed in untreated cohorts. Only PLP-treatment resulted in significant reduction of astrocyte expression at 7 days and percent difference from 24 hr to 7 days. Finally, PLP-treatment significantly reduced the percent difference from 24 hr to 7 days in microglia/macrophage density compared to the untreated control. These results suggest that PLP-treatment addressed acute hypocoagulation and decreased BBB permeability followed by decreased neuroinflammation and fold-change tissue loss by 7 days post-injury. These promising results indicate that PLPs could be a potential therapeutic modality for TBI.
View details for DOI 10.1002/jbm.b.34888
View details for Web of Science ID 000660246500001
View details for PubMedID 34117693
Intranasal Administration for Pain: Oxytocin and Other Polypeptides.
2021; 13 (7)
Pain, particularly chronic pain, remains one of the most debilitating and difficult-to-treat conditions in medicine. Chronic pain is difficult to treat, in part because it is associated with plastic changes in the peripheral and central nervous systems. Polypeptides are linear organic polymers that are highly selective molecules for neurotransmitter and other nervous system receptors sites, including those associated with pain and analgesia, and so have tremendous potential in pain therapeutics. However, delivery of polypeptides to the nervous system is largely limited due to rapid degradation within the peripheral circulation as well as the blood-brain barrier. One strategy that has been shown to be successful in nervous system deposition of polypeptides is intranasal (IN) delivery. In this narrative review, we discuss the delivery of polypeptides to the peripheral and central nervous systems following IN administration. We briefly discuss the mechanism of delivery via the nasal-cerebral pathway. We review recent studies that demonstrate that polypeptides such as oxytocin, delivered IN, not only reach key pain-modulating regions in the nervous system but, in doing so, evoke significant analgesic effects. IN administration of polypeptides has tremendous potential to provide a non-invasive, rapid and effective method of delivery to the nervous system for chronic pain treatment and management.
View details for DOI 10.3390/pharmaceutics13071088
View details for PubMedID 34371778
Sex-Dependent Macromolecule and Nanoparticle Delivery in Experimental Brain Injury
TISSUE ENGINEERING PART A
2020; 26 (13-14): 688-701
The development of effective therapeutics for brain disorders is challenging, in particular, the blood-brain barrier (BBB) severely limits access of the therapeutics into the brain parenchyma. Traumatic brain injury (TBI) may lead to transient BBB permeability that affords a unique opportunity for therapeutic delivery via intravenous administration ranging from macromolecules to nanoparticles (NPs) for developing precision therapeutics. In this regard, we address critical gaps in understanding the range/size of therapeutics, delivery window(s), and moreover, the potential impact of biological factors for optimal delivery parameters. Here we show, for the first time, to the best of our knowledge, that 24-h postfocal TBI female mice exhibit a heightened macromolecular tracer and NP accumulation compared with male mice, indicating sex-dependent differences in BBB permeability. Furthermore, we report for the first time the potential to deliver NP-based therapeutics within 3 days after focal injury in both female and male mice. The delineation of injury-induced BBB permeability with respect to sex and temporal profile is essential to more accurately tailor time-dependent precision and personalized nanotherapeutics. Impact statement In this study, we identified a sex-dependent temporal profile of blood/brain barrier disruption in a preclinical mouse model of traumatic brain injury (TBI) that contributes to starkly different macromolecule and nanoparticle delivery profiles post-TBI. The implications and potential impact of this work are profound and far reaching as it indicates that a demand of true personalized medicine for TBI is necessary to deliver the right therapeutic at the right time for the right patient.
View details for DOI 10.1089/ten.tea.2020.0040
View details for Web of Science ID 000551090000002
View details for PubMedID 32697674
View details for PubMedCentralID PMC7398445
Blood-brainbarrier disruption dictates nanoparticle accumulation following experimental brain injury
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
2018; 14 (7): 2155-2166
Clinically, traumatic brain injury (TBI) results in complex heterogeneous pathology that cannot be recapitulated in single pre-clinical animal model. Therefore, we focused on evaluating utility of nanoparticle (NP)-based therapeutics following three diffuse-TBI models: mildclosed-head injury (mCHI), repetitive-mCHI and midline-fluid percussion injury (FPI). We hypothesized that NP accumulation after diffuse TBI correlates directly with blood-brainbarrier permeability. Mice received PEGylated-NP cocktail (20-500 nm) (intravenously) after single- or repetitive-(1 impact/day, 5 consecutive days) CHI (immediately) and midline-FPI (1 h, 3 h and 6 h). NPs circulated for 1 h before perfusion/brain extraction. NP accumulation was analyzed using fluorescent microscopy in brain regions vulnerable to neuropathology. Minimal/no NP accumulation after mCHI/RmCHI was observed. In contrast, midlineFPI resulted in significant peak accumulation of up to 500 nm NP at 3 h post-injury compared to sham, 1 h, and 6 h groups in the cortex. Therefore, our study provides the groundwork for feasibility of NP-delivery based on NPinjection time and NPsize after mCHI/RmCHI and midline-FPI.
View details for DOI 10.1016/j.nano.2018.06.004
View details for Web of Science ID 000446496900017
View details for PubMedID 29933022
View details for PubMedCentralID PMC6177306
Nanoparticle-Based Therapeutics for Brain Injury
ADVANCED HEALTHCARE MATERIALS
2018; 7 (1)
Brain injuries affect a large patient population with major physical and emotional suffering for patients and their relatives; at a significant cost to the society. Effective diagnostic and therapeutic options available for brain injuries are limited by the complex brain injury pathology involving blood-brain barrier (BBB). Brain injuries, including ischemic stroke and brain trauma, initiate BBB opening for a short period of time, which is followed by a second reopening for an extended time. The leaky BBB and/or the alterations in the receptor expression on BBB may provide opportunities for therapeutic delivery via nanoparticles (NPs). The approaches for therapeutic interventions via NP delivery are aimed at salvaging the pericontusional/penumbra area for possible neuroprotection and neurovascular unit preservation. The focus of this progress report is to provide a survey of NP strategies employed in cerebral ischemia and brain trauma and finally provide insights for improved NP-based diagnostic/treatment approaches.
View details for DOI 10.1002/adhm.201700668
View details for Web of Science ID 000419674600007
View details for PubMedID 29034608
View details for PubMedCentralID PMC5903677
Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size
2016; 6: 29988
Nanoparticle (NP) based therapeutic and theranostic agents have been developed for various diseases, yet application to neural disease/injury is restricted by the blood-brain-barrier (BBB). Traumatic brain injury (TBI) results in a host of pathological alterations, including transient breakdown of the BBB, thus opening a window for NP delivery to the injured brain tissue. This study focused on investigating the spatiotemporal accumulation of different sized NPs after TBI. Specifically, animal cohorts sustaining a controlled cortical impact injury received an intravenous injection of PEGylated NP cocktail (20, 40, 100, and 500 nm, each with a unique fluorophore) immediately (0 h), 2 h, 5 h, 12 h, or 23 h after injury. NPs were allowed to circulate for 1 h before perfusion and brain harvest. Confocal microscopy demonstrated peak NP accumulation within the injury penumbra 1 h post-injury. An inverse relationship was found between NP size and their continued accumulation within the penumbra. NP accumulation preferentially occurred in the primary motor and somatosensory areas of the injury penumbra as compared to the parietal association and visual area. Thus, we characterized the accumulation of particles up to 500 nm at different times acutely after injury, indicating the potential of NP-based TBI theranostics in the acute period after injury.
View details for DOI 10.1038/srep29988
View details for Web of Science ID 000380032200001
View details for PubMedID 27444615
View details for PubMedCentralID PMC4957235